Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 1
2012 4
2013 1
2014 2
2015 1
2018 1
2021 7
2022 9
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R. Sanchez GAM, et al. Among authors: klausmeier t. J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11. J Clin Invest. 2018. PMID: 29649002 Free PMC article.
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Beukelman T, Tomlinson G, Nigrovic PA, Dennos A, Del Gaizo V, Jelinek M, Riordan ME, Schanberg LE, Mohan S, Pfeifer E, Kimura Y; CARRA FROST Investigators. Beukelman T, et al. Pediatr Rheumatol Online J. 2022 Dec 8;20(1):113. doi: 10.1186/s12969-022-00768-6. Pediatr Rheumatol Online J. 2022. PMID: 36482434 Free PMC article.
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S, Dennos AC, Kimura Y, Beukelman T, Shrader P, Phillips TA, Kohlheim M, Schanberg LE, Yeung RSM, Horton DB; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Ringold S, et al. Arthritis Care Res (Hoboken). 2023 Apr;75(4):715-723. doi: 10.1002/acr.24994. Epub 2022 Dec 21. Arthritis Care Res (Hoboken). 2023. PMID: 35921198
Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Woo JMP, Simmonds F, Dennos A, Son MBF, Lewandowski LB, Rubinstein TB; CARRA Registry investigators. Woo JMP, et al. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2285-2294. doi: 10.1002/acr.25136. Epub 2023 May 30. Arthritis Care Res (Hoboken). 2023. PMID: 37093036
Reactive arthritis: a review.
Kim PS, Klausmeier TL, Orr DP. Kim PS, et al. Among authors: klausmeier tl. J Adolesc Health. 2009 Apr;44(4):309-15. doi: 10.1016/j.jadohealth.2008.12.007. Epub 2009 Feb 12. J Adolesc Health. 2009. PMID: 19306788 Review.
Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.
Peng J, Dönnes P, Ardoin SP, Schanberg LE, Lewandowski L; APPLE trial investigators and Childhood Rheumatology Research Alliance (CARRA); Robinson G, Jury EC, Ciurtin C. Peng J, et al. Arthritis Rheumatol. 2024 Mar;76(3):455-468. doi: 10.1002/art.42722. Epub 2023 Dec 19. Arthritis Rheumatol. 2024. PMID: 37786302 Clinical Trial.
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
Mannion ML, Amin S, Balevic S, Chang ML, Correll CK, Kearsley-Fleet L, Hyrich KL, Beukelman T; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators. Mannion ML, et al. Arthritis Care Res (Hoboken). 2024 Mar 31. doi: 10.1002/acr.25339. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 38556945
34 results